NYSE:BIO - Bio-Rad Laboratories Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$272.96 -3.46 (-1.25 %)
(As of 11/12/2018 01:02 PM ET)
Previous Close$276.42
Today's Range$270.76 - $274.46
52-Week Range$231.00 - $345.15
Volume3,305 shs
Average Volume202,399 shs
Market Capitalization$8.25 billion
P/E Ratio66.76
Dividend YieldN/A
Beta1.07
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNYSE:BIO
Previous Symbol
CUSIP09057220
Phone510-724-7000

Debt

Debt-to-Equity Ratio0.09
Current Ratio4.49
Quick Ratio3.16

Price-To-Earnings

Trailing P/E Ratio66.76
Forward P/E Ratio49.90
P/E Growth3.37

Sales & Book Value

Annual Sales$2.16 billion
Price / Sales3.77
Cash Flow$4.0862 per share
Price / Cash66.80
Book Value$164.26 per share
Price / Book1.66

Profitability

EPS (Most Recent Fiscal Year)$4.10
Net Income$122.24 million
Net Margins55.13%
Return on Equity3.72%
Return on Assets2.67%

Miscellaneous

Employees3,270
Outstanding Shares29,830,000
Market Cap$8.25 billion
OptionableOptionable

Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

How will Bio-Rad Laboratories' stock buyback program work?

Bio-Rad Laboratories declared that its board has approved a stock buyback program on Wednesday, November 29th 2017, which authorizes the company to repurchase $250,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company's board of directors believes its stock is undervalued.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) issued its earnings results on Thursday, November, 1st. The medical research company reported $0.91 earnings per share for the quarter, missing the Zacks' consensus estimate of $1.16 by $0.25. The medical research company had revenue of $545.10 million for the quarter, compared to analysts' expectations of $541.23 million. Bio-Rad Laboratories had a net margin of 55.13% and a return on equity of 3.72%. The business's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.91 earnings per share. View Bio-Rad Laboratories' Earnings History.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Bio-Rad Laboratories.

What price target have analysts set for BIO?

7 brokerages have issued 1-year target prices for Bio-Rad Laboratories' shares. Their predictions range from $290.00 to $420.00. On average, they anticipate Bio-Rad Laboratories' share price to reach $339.1667 in the next year. This suggests a possible upside of 25.1% from the stock's current price. View Analyst Price Targets for Bio-Rad Laboratories.

What is the consensus analysts' recommendation for Bio-Rad Laboratories?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bio-Rad Laboratories.

What are Wall Street analysts saying about Bio-Rad Laboratories stock?

Here are some recent quotes from research analysts about Bio-Rad Laboratories stock:
  • 1. Jefferies Financial Group Inc analysts commented, "We see substantial hidden value in BIO’s droplet digital PCR (ddPCR) franchise that is under-appreciated by investors." (9/24/2018)
  • 2. According to Zacks Investment Research, "Bio-Rad exited second-quarter 2018 on a solid note, with year-over-year growth in earnings and revenues. Sales growth at the Clinical Diagnostics’ segment was impressive as well. The company also registered strong growth in Life Science, cell biology, Digital PCR and food safety product lines. Further, solid growth in geographies like North America, China and Asia Pacific reflects strong international foothold. Improvement in operating income is a major positive. The company’s raised revenue growth guidance is indicative of bright prospects. Bio-Rad has been outperforming its industry over the past year. However, challenges associated with successful implementation of the global ERP system is a concern. Further, Bio-Rad is exposed to risks associated with a weaker global economy and lower reimbursement rates. Also, declining gross margin is a concern." (8/13/2018)

Has Bio-Rad Laboratories been receiving favorable news coverage?

Media coverage about BIO stock has been trending somewhat positive on Monday, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bio-Rad Laboratories earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future.

Who are some of Bio-Rad Laboratories' key competitors?

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the folowing people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 68)
  • Ms. Christine A. Tsingos, Exec. VP & CFO (Age 59)
  • Mr. John Goetz, Consultant (Age 68)
  • Mr. John Hertia, Exec. VP & Pres of Clinical Diagnostics Group (Age 62)
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 56)

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.26%), Acadian Asset Management LLC (2.36%), Wells Fargo & Company MN (2.31%), American Century Companies Inc. (2.30%), Alliancebernstein L.P. (0.90%) and Fisher Asset Management LLC (0.86%). Company insiders that own Bio-Rad Laboratories stock include Christine A Tsingos, Giovanni Magni, James R Stark and Michael Crowley. View Institutional Ownership Trends for Bio-Rad Laboratories.

Which institutional investors are selling Bio-Rad Laboratories stock?

BIO stock was sold by a variety of institutional investors in the last quarter, including Fort Washington Investment Advisors Inc. OH, Acadian Asset Management LLC, Wells Fargo & Company MN, WINTON GROUP Ltd, FIL Ltd, Los Angeles Capital Management & Equity Research Inc., Monarch Partners Asset Management LLC and Assenagon Asset Management S.A.. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include Christine A Tsingos, Giovanni Magni, James R Stark and Michael Crowley. View Insider Buying and Selling for Bio-Rad Laboratories.

Which institutional investors are buying Bio-Rad Laboratories stock?

BIO stock was acquired by a variety of institutional investors in the last quarter, including Bodenholm Capital AB, First Trust Advisors LP, GW&K Investment Management LLC, Prudential Financial Inc., Columbus Circle Investors, Russell Investments Group Ltd., Canada Pension Plan Investment Board and Artemis Investment Management LLP. View Insider Buying and Selling for Bio-Rad Laboratories.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $271.06.

How big of a company is Bio-Rad Laboratories?

Bio-Rad Laboratories has a market capitalization of $8.25 billion and generates $2.16 billion in revenue each year. The medical research company earns $122.24 million in net income (profit) each year or $4.10 on an earnings per share basis. Bio-Rad Laboratories employs 3,270 workers across the globe.

What is Bio-Rad Laboratories' official website?

The official website for Bio-Rad Laboratories is http://www.bio-rad.com.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]


MarketBeat Community Rating for Bio-Rad Laboratories (NYSE BIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  264 (Vote Outperform)
Underperform Votes:  259 (Vote Underperform)
Total Votes:  523
MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories and other stocks. Vote "Outperform" if you believe BIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/12/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel